StarTric has finalised a new seed financing round to advance its next-generation technology for the transcatheter repair of the tricuspid heart valve.
The company has developed an approach combining a minimally invasive percutaneous procedure with the ‘Clover’ edge-to-edge surgical technique developed by Ottavio Alfieri and Michele De Bonis (both San Raffaele University Hospital, Milan, Italy).
“The funds from this round will be used to finalise the design of a minimally invasive device that is aimed at treating tricuspid regurgitation (TR) with unprecedented efficacy, ability to be “personalised” to each patient, and ease of use. This milestone is of the utmost importance, as its achievement will pave the way to the production of the investigational device for the first-in-human trial,” said Daniele Zanotti, CEO of StarTric.
“We have achieved several key development milestones and received significant interest and appreciation within the interventional cardiology community at the recent EuroPCR conference. We are also very glad with the vote of confidence of our investors and the intense teamwork with our clinical partners to accelerate the company towards clinical use,” said Eugenio Passanante, founder and CFO.
The funding round, also following the A-Road acceleration and fundraising programme, saw participation from experienced early-stage investors, including NLC Health Impact Fund, Growth Engine, and Business Angels.
